# A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)

> **NCT04598451** · PHASE3 · COMPLETED · sponsor: **argenx** · enrollment: 222 (actual)

## Conditions studied

- Pemphigus Vulgaris
- Pemphigus Foliaceus

## Interventions

- **BIOLOGICAL:** efgartigimod PH20 SC
- **OTHER:** Placebo
- **DRUG:** prednisone

## Key facts

- **NCT ID:** NCT04598451
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-01
- **Primary completion:** 2023-08-22
- **Final completion:** 2023-08-22
- **Target enrollment:** 222 (ACTUAL)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04598451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04598451, "A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04598451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*